Inactive Instrument

Luckwel Pharmaceuticals Inc. Stock Other OTC

LWEL

US54959L1017

Chart Luckwel Pharmaceuticals Inc.

Duration

Period

Style

Dynamic Chart

Latest news about Luckwel Pharmaceuticals Inc.

Luckwel Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended June 30, 2020	21-09-07	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2020	21-06-10	CI
Luckwel Pharmaceuticals Inc. announced that it expects to receive $0.075 million in funding from Bounty Company Limited	21-05-13	CI
Luckwel Pharmaceuticals Inc. announced that it expects to receive $0.12 million in funding	21-04-19	CI
Luckwel Pharmaceuticals Inc. Announces Address Changes	21-01-04	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2019	20-02-13	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2019	19-11-14	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2019	19-07-02	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018	19-02-14	CI
Luckycom Pharmaceuticals Inc. has Changed its Name to Luckwel Pharmaceuticals Inc	18-04-13	CI
Luckwel Pharmaceuticals Inc. has Changed its Ticker to LWEL from LCOM	18-04-13	CI
Luckycom, Inc. will Change its Name to Luckycom Pharmaceuticals Inc	17-04-18	CI
Luckycom Pharmaceuticals Inc. will Change its Ticker to LCOM from LKYM	17-04-18	CI
Luckycom Inc Auditor Raises 'Going Concern' Doubt	16-05-01	CI
Luckycom Inc Announces Fiscal Year Change from February 28 or 29 to March 31	16-02-11	CI

More news

Press releases Luckwel Pharmaceuticals Inc.

LUCKWEL PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	21-10-01	AQ
LUCKWEL PHARMACEUTICALS : Changes in Registrant's Certifying Accountant, Non-Reliance on Previous Financials, Audits or Interim Review, Financial Statements and Exhibits (form 8-K/A)	21-09-22	AQ
LUCKWEL PHARMACEUTICALS INC. : Changes in Registrant's Certifying Accountant, Non-Reliance on Previous Financials, Audits or Interim Review (form 8-K)	21-09-21	AQ
LUCKWEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	21-09-09	AQ
LUCKWEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	21-09-07	AQ

More press releases

Managers and Directors - Luckwel Pharmaceuticals Inc.

Managers	Title	Age	Since
Kingrich Lee CEO	Chief Executive Officer	49	13-01-01
Mark Carrao DFI	Director of Finance/CFO	-	21-08-31
Michael Silverman CTO	Chief Tech/Sci/R&D Officer	-	-

Members of the board	Title	Age	Since
Kingrich Lee CEO	Chief Executive Officer	49	13-01-01

More insiders

Luckwel Pharmaceuticals Inc. creates medicine to cure diseases. The Company is focused on autoimmune disease, human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) and infectious diseases. The Companyâs pipelines include LWEL-2120 for the treatment of rheumatoid arthritis (RA), LWEL-2119 for the treatment of HIV and LWEL-2103 for the treatment of COVID-19.

Sector

Investment Holding Companies

More about the company

Sector Shell Companies

	1st Jan change	Capi.
TRUMP MEDIA & TECHNOLOGY GROUP CORP.	+119.94%	4.88B
SCREAMING EAGLE ACQUISITION CORP.	+1.60%	1.01B
CHURCHILL CAPITAL CORP VII	+2.29%	982M
APPLE ISPORTS GROUP, INC.	+41.91%	872M
PERELLA WEINBERG PARTNERS	+27.64%	836M
ARES ACQUISITION CORPORATION II	+1.68%	663M
E7 GROUP	+1.80%	610M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	600M
ALTC ACQUISITION CORP.	+23.11%	578M

Shell Companies